| 產(chǎn)品編號 | bsm-33176M-PE-Cy5.5 |
| 英文名稱 | Mouse Anti-eNOS/PE-Cy5.5 Conjugated antibody |
| 中文名稱 | PE-Cy5.5標(biāo)記的一氧化氮合成酶-3（內(nèi)皮型）單克隆抗體 |
| 別 名 | NOS-3; cNOS; Constitutive NOS; EC NOS; ecNOS; Endothelial nitric oxidase synthase; Endothelial nitric oxide synthase; Endothelial nitric oxide synthase 3; Endothelial NOS; Nitric oxide synthase 3 (endothelial cell); Nitric oxide synthase 3; Nitric oxide synthase 3 endothelial cell; Nitric oxide synthase endothelial; nitric oxide synthase, endothelial; NOS 3; NOS III; NOS type III; NOS3; NOSIII; NOS3_HUMAN. |
| 規(guī)格價格 | 100ul/2980元 購買 大包裝/詢價 |
| 說 明 書 | 100ul |
| 研究領(lǐng)域 | 細(xì)胞生物 神經(jīng)生物學(xué) 信號轉(zhuǎn)導(dǎo) 合成與降解 內(nèi)皮細(xì)胞 |
| 抗體來源 | Mouse |
| 克隆類型 | Monoclonal |
| 克 隆 號 | 8G1 |
| 交叉反應(yīng) | Mouse, (predicted: Human, Rat, ) |
| 產(chǎn)品應(yīng)用 | ICC=1:50-200 IF=1:50-200
not yet tested in other applications. optimal dilutions/concentrations should be determined by the end user. |
| 分 子 量 | 133kDa |
| 性 狀 | Lyophilized or Liquid |
| 濃 度 | 1mg/ml |
| 免 疫 原 | Recombinant human eNOS Protein |
| 亞 型 | IgG |
| 純化方法 | affinity purified by Protein G |
| 儲 存 液 | Preservative: 15mM Sodium Azide, Constituents: 1% BSA, 0.05M PB, pH 7.5. |
| 保存條件 | Store at -20 °C for one year. Avoid repeated freeze/thaw cycles. The lyophilized antibody is stable at room temperature for at least one month and for greater than a year when kept at -20°C. When reconstituted in sterile pH 7.4 0.01M PBS or diluent of antibody the antibody is stable for at least two weeks at 2-4 °C. |
| 產(chǎn)品介紹 |
background: Nitric oxide synthase NOS oxidizes a guanidine nitrogen of arginine releasing nitric oxide in the form of a free radical and citrulline. Nitric oxide thus generated acts as a messenger in diverse functions including vasodilation neurotransmission, anti tumor and anti pathogenic activities. NOS is classified under three types: neuronal NOS (nNOS) or brain NOS (bNOS); inducible NOS (iNOS) or macrophage NOS (mNOS); and endothelial NOS (eNOS). eNOS is a calcium/calmodulin dependent enzyme which undergoes several post translational modifications, including acylation with myristate and palmitate, and phosphorylation on numerous residues. As with the other members of the NOS family, eNOS derives the diffusible multifunctional second messenger NO from L arginine through a series of reactions in which L citrulline is an intermediate. eNOS plays an important role in controlling vascular tone, platelet aggregation, and cardiac myocyte function. Function: Produces nitric oxide (NO) which is implicated in vascular smooth muscle relaxation through a cGMP-mediated signal transduction pathway. NO mediates vascular endothelial growth factor (VEGF)-induced angiogenesis in coronary vessels and promotes blood clotting through the activation of platelets. Isoform eNOS13C: Lacks eNOS activity, dominant-negative form that may down-regulate eNOS activity by forming heterodimers with isoform 1. Subunit: Homodimer. Interacts with NOSIP and NOSTRIN. Subcellular Location: Cell membrane. Membrane, caveola. Cytoplasm, cytoskeleton. Golgi apparatus. Note=Specifically associates with actin cytoskeleton in the G2 phase of the cell cycle; which is favored by interaction with NOSIP and results in a reduced enzymatic activity. Tissue Specificity: Platelets, placenta, liver and kidney. Post-translational modifications: Phosphorylation by AMPK at Ser-1177 in the presence of Ca(2+)-calmodulin (CaM) activates activity. In absence of Ca(2+)-calmodulin, AMPK also phosphorylates Thr-495, resulting in inhibition of activity. Phosphorylation of Ser-114 by CDK5 reduces activity. Similarity: Belongs to the NOS family. Contains 1 FAD-binding FR-type domain. Contains 1 flavodoxin-like domain. Database links: Important Note: This product as supplied is intended for research use only, not for use in human, therapeutic or diagnostic applications. 合成與降解（Synthesis and Degradation) 催化生物體內(nèi)一氧化氮（NO）生成的酶。分神經(jīng)型一氧化氮合成的酶（nNOS or NOS-1）、誘導(dǎo)型一氧化氮合成的酶（iNOS or NOS-2）、內(nèi)皮型一氧化氮合成的酶（eNOS or NOS-3）。此抗體識別分子量為135kDa的內(nèi)皮型一氧化氮合成的酶。 |
